CardioGenics (OTCMKTS:CGNH) and Phreesia (NYSE:PHR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.
This table compares CardioGenics and Phreesia’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent recommendations and price targets for CardioGenics and Phreesia, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Phreesia has a consensus price target of $30.40, suggesting a potential upside of 7.50%. Given Phreesia’s higher possible upside, analysts plainly believe Phreesia is more favorable than CardioGenics.
Insider & Institutional Ownership
70.8% of Phreesia shares are held by institutional investors. 41.4% of CardioGenics shares are held by company insiders. Comparatively, 28.2% of Phreesia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings and Valuation
This table compares CardioGenics and Phreesia’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Phreesia||$124.78 million||8.54||-$20.29 million||($4.50)||-6.28|
CardioGenics has higher earnings, but lower revenue than Phreesia.
CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process and an integrated payments solution for processing of patient payments. It deploys its platform in a range of modalities, including through Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a Web-based dashboard for providers; PhreesiaPads, which are self-service intake tablets; and Arrivals Stations that are on-site kiosks. The company's Phreesia Platform provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; clinical support solution that collects clinical intake and PRO data for approximately 25 specialties; appointments solution for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. It serves patients, healthcare provider organizations, and life sciences companies. The company was founded in 2005 and is headquartered in New York, New York.
Receive News & Ratings for CardioGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CardioGenics and related companies with MarketBeat.com's FREE daily email newsletter.